Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies

Chemical Biology and Drug Design

Volumn 70, Issue 1, 2007, Pages 1-12

  Huth, Jeffrey R ^a   Park, Chang ^a   Petros, Andrew M ^a   Kunzer, Aaron R ^a   Wendt, Michael D ^a   Wang, Xilu ^a   Lynch, Christopher L ^a   Mack, Jamey C ^a   Swift, Kerry M ^a   Judge, Russell A ^a   Chen, Jun ^a   Richardson, Paul L ^a   Jin, Sha ^a   Tahir, Stephen K ^a   Matayoshi, Edward D ^a   Dorwin, Sarah A ^a   Ladror, Uri S ^a   Severin, Jean M ^a   Walter, Karl A ^a   Bartley, Diane M ^a   Fesik, Stephen W ^a   Elmore, Steven W ^a   Hajduk, Philip J ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

Drug Design; Heat Shock Protein; NMR Screening; Structure Based Drug Design

Indexed keywords

ENZYME; HEAT SHOCK PROTEIN 90 INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER THERAPY; CONFORMATION; DRUG DESIGN; ENZYME ACTIVE SITE; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SYNTHESIS;

AMINOPYRIDINES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION;

EID: 34447297884     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00535.x     Document Type: Article

References (27)

1. Solit D.B., Rosen N. (2006) Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6 : 1205 1214.
2. Cullinan S.B., Whitesell L. (2006) Heat shock protein 90: a unique chemotherapeutic target. Semin Oncol 33 : 457 465.
3. Zhao R., Davey M., Hsu Y.C., Kaplanek P., Tong A., Parsons A.B., Krogan N., Cagney G., Mai D., Greenblatt J., Boone C., Emili A., Houry W.A. (2005) Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 120 : 715 727.
4. Gooljarsingh L.T., Fernandes C., Yan K., Zhang H., Grooms M., Johanson K., Sinnamon R.H., Kirkpatrick R.B., Kerrigan J., Lewis T., Arnone M., King A.J., Lai Z., Copeland R.A., Tummino P.J. (2006) A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci U S A 103 : 7625 7630.
5. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425 : 407 410.
6. Chadli A., Bouhouche I., Sullivan W., Stensgard B., McMahon N., Catelli M.G., Toft D.O. (2000) Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90. Proc Natl Acad Sci USA 97 : 12524 12529.
7. Ali M.M., Roe S.M., Vaughan C.K., Meyer P., Panaretou B., Piper P.W., Prodromou C., Pearl L.H. (2006) Crystal structure of an Hsp90-nucleotide-p23/ Sba1 closed chaperone complex. Nature 440 : 1013 1017.
8. Meyer P., Prodromou C., Hu B., Vaughan C., Roe S.M., Panaretou B., Piper P.W., Pearl L.H. (2003) Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell 11 : 647 658.
9. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89 : 239 250.
10. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42 : 260 266.
11. Huai Q., Wang H., Liu Y., Kim H.Y., Toft D., Ke H. (2005) Structures of the N-terminal and middle domains of E. coli Hsp90 and conformation changes upon ADP binding. Structure 13 : 579 590.
12. McDonald E., Workman P., Jones K. (2006) Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr Top Med Chem 6 : 1091 1107.
13. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. (1996) Discovering high-affinity ligands for proteins - SAR by NMR. Science 274 : 1531 1534.
14. Hajduk P.J., Meadows R.P., Fesik S.W. (1997) Drug design - discovering high-affinity ligands for proteins. Science 278 : 497 499.
15. Hajduk P.J., Augeri D.J., Mack J., Mendoza R., Yang J.G., Betz S.F., Fesik S.W. (2000) NMR-based screening of proteins containing C-13-labeled methyl groups. J Am Chem Soc 122 : 7898 7904.
16. Hajduk P.J., Sheppard G., Nettesheim D.G., Olejniczak E.T., Shuker S.B., Meadows R.P., Steinman D.H. et al. (1997) Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc 119 : 5818 5827.
17. Cele A.Z., Metz J.T. (2005) Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 10 : 464 469.
18. Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90 : 65 75.
19. Hajduk P.J. (2006) Fragment-based drug design: how big is too big J Med Chem 49 : 6972 6976.
20. Hajduk P.J., Greer J. (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6 : 211 219.
21. Erlanson D.A., McDowell R.S., O'Brien T. (2004) Fragment-based drug discovery. J Med Chem 47 : 3463 3482.
22. Hajduk P.J., Huth J.R., Sun C. (2006) SAR by NMR: an analysis of potency gains realized through fragment-linking and fragment-elaboration strategies for lead generation. In : Jahnke W., Erlanson D.A., editors. Fragment-based Approaches in Drug Discovery. Weinheim : Wiley-VCH p. 181 192.
23. Huth J.R., Sun C., Sauer D.R., Hajduk P.J. (2005) Utilization of NMR-derived fragment leads in drug design. Methods Enzymol 394 : 549 571.
24. Maes V., Engelborghs Y., Hoebeke J., Maras Y., Vercruysse A. (1982) Fluorimetric analysis of the binding of warfarin to human serum albumin. Equilibrium and kinetic study. Mol Pharmacol 21 : 100 107.
25. Goto N.K., Gardner K.H., Mueller G.A., Willis R.C., Kay L.E. (1999) A robust and cost-effective method for the production of Val, Leu, Ile (delta 1) methyl-protonated 15N-, 13C-, 2H-labeled proteins. J Biomol NMR 13 : 369 374.
26. Wright L. et al. (2004) Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol 11 : 775 785.
27. Zhou V., Han S., Brinker A., Klock H., Caldwell J., Gu X.J. (2004) A time-resolved fluorescence resonance energy transfer-based HTS assay and a surface plasmon resonance-based binding assay for heat shock protein 90 inhibitors. Anal Biochem 331 : 349 357.